Avoid Nimotop IV if you have a known hypersensitivity to nimodipine or any of its components. This includes prior instances of allergic reactions, such as rash, itching, or swelling. Monitor patients closely for any signs of hypersensitivity during and after infusion.
Specific Patient Populations
Exercise caution when administering Nimotop IV to patients with impaired hepatic function. Reduce the dosage accordingly, based on clinical assessment and liver function tests. Similarly, carefully adjust the dose for patients with severe renal impairment. Closely monitor blood pressure and other vital signs in both these groups.
Nimodipine can interact with various medications. Concurrent use with CYP3A4 inhibitors, like ketoconazole or erythromycin, can significantly increase nimodipine plasma concentrations, potentially leading to increased adverse effects. Conversely, inducers of CYP3A4, such as rifampin, may decrease nimodipine levels, reducing its efficacy. Consult drug interaction resources before administering Nimotop IV concurrently with other medications.
Avoid concomitant use with beta-blockers, as this combination may result in excessive bradycardia. Also, be aware of the potential for increased risk of hypotension when using Nimodipine IV with other hypotensive agents.
During treatment, regularly assess for side effects such as headache, flushing, hypotension, and nausea. Promptly report and manage any adverse reactions appropriately. Closely monitor blood pressure throughout the infusion and after its completion.
